A Randomized, Double Blind Placebo Controlled 2-Arm Parallel Group, Multicenter Study With A 16-Week Treatment Assessing The Efficacy And Safety, And 52-Week Long Term Safety Including 36-Week Open Label Extension Of Tofogliflozin With Insulin Treatment In Type 2 Diabetes Mellitus
Phase of Trial: Phase IV
Latest Information Update: 01 Feb 2017
At a glance
- Drugs Tofogliflozin (Primary) ; Insulin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Sanofi
- 07 Jun 2017 Biomarkers information updated
- 23 Jan 2017 Status changed from active, no longer recruiting to completed.
- 05 Jan 2016 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.